1. Home
  2. Directory
  3. Michigan
  4. Ann Arbor
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1043574098

JORDAN KENDALL SCHAEFER MD
Prescription History 1043574098
Internal Medicine - Hematology in Ann Arbor, MI

NPI Status: Active since June 25, 2012

Contact Information

1500 EAST MEDICAL CENTER DR
B1 FLOOR CANCER RECP 'B'
ANN ARBOR, MI
ZIP 48109
Phone: (734) 647-8901

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for JORDAN KENDALL SCHAEFER MD, an active Hematology specialist practicing in Ann Arbor, MI. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 177 documented patient claims. Among these therapy options, the most frequently utilized medication is Eliquis, which accounts for 55 claims alone.

Medication Index

E
H
P
W
X
No matching medications currently found on file.

Eliquis

Generic Formulation: ApixabanSpecialty: Hematology
Provider Metrics Summary
Total Claims 55
30-Day Fills 129.5
Days Supply 3,865
MI State Average Benchmarks
Peer Average Claims76.0
Peer Average 30-Day Fills135.2
Peer Average Days Supply3,873
Conservative Utilization

This provider writes prescriptions for this formulation 27.6% less frequently than the standard regional baseline metric for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $66,914.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,216.64

State Avg Cost Per Claim

$879.34

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Enoxaparin Sodium

Generic Formulation: Enoxaparin SodiumSpecialty: Hematology
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.0
Days Supply 635
MI State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills23.4
Peer Average Days Supply306
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,654.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$463.25

State Avg Cost Per Claim

$180.52

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Enoxaparin is used to prevent and treat harmful blood clots. This helps to reduce the risk of a stroke or heart attack. This medication helps keep your blood flowing smoothly by lowering the activity of clotting proteins in the blood. Enoxaparin is an anticoagulant, also known as a blood thinner. It is a type of heparin. Conditions which increase your risk of developing blood clots include certain types of surgeries (such as knee/hip replacement, abdominal), long periods of being immobile, certain types of heart attack, and a specific type of chest pain called unstable angina. For some medical conditions, enoxaparin may be used in combination with other blood thinners.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Hematology
Provider Metrics Summary
Total Claims 15
30-Day Fills 23.9
Days Supply 688
MI State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills70.7
Peer Average Days Supply2,093
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.5% less volume than the regional standard for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $468.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$31.24

State Avg Cost Per Claim

$38.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Prednisone

Generic Formulation: PrednisoneSpecialty: Hematology
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.3
Days Supply 365
MI State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills55.5
Peer Average Days Supply991
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 68.2% less volume than the regional standard for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $72.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.17

State Avg Cost Per Claim

$5.76

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Warfarin Sodium

Generic Formulation: Warfarin SodiumSpecialty: Hematology
Provider Metrics Summary
Total Claims 31
30-Day Fills 81.5
Days Supply 2,387
MI State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills82.4
Peer Average Days Supply2,366
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $713.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$23.00

State Avg Cost Per Claim

$14.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.

Therapeutic Applications

This medication is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and/or to prevent new clots from forming in your body. Preventing harmful blood clots helps to reduce the risk of a stroke or heart attack. Conditions that increase your risk of developing blood clots include a certain type of irregular heart rhythm (atrial fibrillation), heart valve replacement, recent heart attack, and certain surgeries (such as hip/knee replacement). Warfarin is commonly called a blood thinner, but the more correct term is anticoagulant. It helps to keep blood flowing smoothly in your body by decreasing the amount of certain substances (clotting proteins) in your blood.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Hematology
Provider Metrics Summary
Total Claims 39
30-Day Fills 93.0
Days Supply 2,790
MI State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills80.8
Peer Average Days Supply2,339
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $49,010.79 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,256.69

State Avg Cost Per Claim

$965.31

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like JORDAN KENDALL SCHAEFER MD provides transparency into local medical care patterns within Ann Arbor, MI.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.